SSRI vs NDRI: Which Is Better for Post-Stroke Depression?
A recent study has compared the effectiveness of fluoxetine and bupropion for treating post-stroke depression. Bupropion showed a lower risk of suicidal ideation, while fluoxetine was more effective in reducing demoralization and apathy. The findings emphasize the need for personalized treatment approaches based on individual symptoms.
- ▪Bupropion was associated with a significantly lower risk for suicidal ideation compared to fluoxetine.
- ▪Fluoxetine was more effective in decreasing demoralization and apathy than bupropion.
- ▪The study included data from over 100,000 patients diagnosed with post-stroke depression.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/ssri-vs-ndri-which-better-post-stroke-depression-2026a1000g2h?src=rss |
| Publication time | Mon, 18 May 2026 13:55:24 EDT |
| Retrieval time | 2026-05-18T18:04:56.852Z |
| Last seen | 2026-05-18T18:04:56.852Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | kHTurZicLb0C |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
SAN FRANCISCO — The selective serotonin reuptake inhibitor (SSRI) fluoxetine and the norepinephrine-dopamine reuptake inhibitor (NDRI) bupropion are each effective for different psychiatric symptoms of post-stroke depression (PSD), new research suggests. In a large retrospective cohort study with data for more than 100,000 patients with PSD, bupropion was associated with a significantly lower risk for suicidal ideation — the primary outcome — compared to treatment with fluoxetine.However, for the secondary outcome of decreased demoralization and apathy, fluoxetine was the winner. The results highlight the importance of customizing PSD treatment to the patient, said investigator Jaime Villa, an incoming first-year medical student at Reading Hospital, Tower Health System.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
